PMV Pharma Q3 2021 net loss $39.5M for nine months; cash $326.3M

PMV Pharmaceuticals, Inc.

2022-Q3 EPS reported -$0.88

Net loss for nine months ended Sep 30, 2021: $39.5M vs $24.0M in prior-year period.
Cash, equivalents and marketable securities: $326.3M as of Sep 30, 2021; sufficient through end of 2023.
R&D expenses increased to $24.3M (from $17.8M) driven by PC14586 clinical development.
Phase 1/2 trial of p53 Y220C reactivator PC14586 data expected in first half 2022.
Appointed Tim Smith as SVP, Head of Corporate Development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.